Table 1.

Overview of clinical studies comparing 7vCRM and PHiD-CV

StudyCountryVaccine groupsaPrimary vaccination scheduleNo. of infants in 7vCRM groupReference
AFinland, France, Poland (primary study 001)PHiD-CV + DTPa-HBV-IPV/Hibb 7vCRM + DTPa-HBV-IPV/Hib2-3-4 months41537
BGermany, Poland, Spain (primary study 011)PHiD-CV + DTPa-HBV-IPV + Hib-MenC-TT 7vCRM + DTPa-HBV-IPV + Hib-MenC-TT2-4-6 months39046
C′Poland (primary study 012)PHiD-CV + DTPw-HBV/Hib + IPV 7vCRM + DTPw-HBV/Hib + IPV2-4-6 months1032
C"Philippines (primary study 012)PHiD-CV + DTPw-HBV/Hib + OPV 7vCRM + DTPw-HBV/Hib + OPV6-10-14 weeks1002
DKorea (primary study 036)PHiD-CV + Hib 7vCRM + Hib2-4-6 months12918
  • a DTPa-HBV-IPV/Hib, diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated poliovirus/Haemophilus influenzae type b vaccine; DTPw-HBV/Hib, diphtheria-tetanus-whole-cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine; IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; Hib-MenC, Haemophilus influenzae type b-Neisseria meninigitis group C conjugate vaccine; Hib, Haemophilus influenzae type b vaccine. All vaccines were manufactured by GSK Biologicals, Rixensart, Belgium, except 7vCRM (Pfizer, Inc.).

  • b In France, the second PCV dose was co-administered with DTPa-IPV/Hib.